Editorial

Re-engineering anti-CTLA-4 antibodies for enhancing cancer immunotherapy efficacy and safety

  • Received: 17 September 2019 Accepted: 18 September 2019 Published: 19 September 2019
  • Citation: Sharvesh Raj Seeruttun. Re-engineering anti-CTLA-4 antibodies for enhancing cancer immunotherapy efficacy and safety[J]. AIMS Genetics, 2019, 6(3): 64-66. doi: 10.3934/genet.2019.3.64

    Related Papers:



  • 加载中


    [1] Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264. doi: 10.1038/nrc3239
    [2] Byun DJ, Wolchok JD, Rosenberg LM, et al. (2017) Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 13: 195-207. doi: 10.1038/nrendo.2016.205
    [3] Yan L, Zhang W (2018) Precision medicine becomes reality-tumor type-agnostic therapy. Cancer Commun 38: 6. doi: 10.1186/s40880-018-0274-3
    [4] Brahmer JR, Tykodi SS, Chow LQ, et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455-2465. doi: 10.1056/NEJMoa1200694
    [5] Weber JS, Yang JC, Atkins MB, et al. (2015) Toxicities of Immunotherapy for the Practitioner. J Clin Oncol 33: 2092-2099. doi: 10.1200/JCO.2014.60.0379
    [6] Blank CU, Rozeman EA, Fanchi LF, et al. (2018) Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med 24: 1655-1661. doi: 10.1038/s41591-018-0198-0
    [7] Chinese Journal of Cancer (2017) The 150 most important questions in cancer research and clinical oncology series: Questions 50-56. Chin J Cancer 36: 69. doi: 10.1186/s40880-017-0236-1
    [8] Rossi JF, Ceballos P, Lu ZY (2019) Immune precision medicine for cancer: A novel insight based on the efficiency of immune effector cells. Cancer Commun 39: 34. doi: 10.1186/s40880-019-0379-3
    [9] Devecchi A, De Cecco L, Dugo M, et al. (2018) The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial-mesenchymal transition, and immune response. Cancer Commun 38: 70. doi: 10.1186/s40880-018-0339-3
    [10] Zhang Y, Du X, Liu M, et al. (2019) Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy. Cell Res 29: 609-627. doi: 10.1038/s41422-019-0184-1
    [11] Hou TZ, Verma N, Wanders J, et al. (2017) Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations. Blood 129: 1458-1468. doi: 10.1182/blood-2016-10-745174
    [12] Du X, Tang F, Liu M, et al. (2018) A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. Cell Res 28: 416-432. doi: 10.1038/s41422-018-0011-0
  • Reader Comments
  • © 2019 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(888) PDF downloads(446) Cited by(0)

Article outline

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog